Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 15,516 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 15,516 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $92.18, for a total value of $1,430,264.88. Following the transaction, the chief financial officer now directly owns 1,726 shares in the company, valued at $159,102.68. This trade represents a 89.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, March 26th, Kevin Feeley sold 8,746 shares of GeneDx stock. The stock was sold at an average price of $95.61, for a total transaction of $836,205.06.
• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $362,565.79.
• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total value of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $21,582.00.

GeneDx Stock Down 4.8 %

Shares of WGS stock traded down $4.67 during trading on Thursday, hitting $92.62. 794,878 shares of the company were exchanged, compared to its average volume of 667,558. The business’s 50-day simple moving average is $89.49 and its 200 day simple moving average is $77.32. GeneDx Holdings Corp. has a twelve month low of $8.63 and a twelve month high of $115.60. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of -47.25 and a beta of 1.93. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. The business had revenue of $95.64 million for the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group lifted their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. TD Cowen upped their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $72.33.

Hedge Funds Weigh In On GeneDx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in WGS. GAMMA Investing LLC boosted its stake in shares of GeneDx by 22,194.3% during the 1st quarter. GAMMA Investing LLC now owns 38,792 shares of the company’s stock worth $3,436,000 after acquiring an additional 38,618 shares in the last quarter. Wellington Management Group LLP bought a new stake in GeneDx during the fourth quarter worth approximately $10,821,000. California State Teachers Retirement System grew its holdings in GeneDx by 13.3% during the fourth quarter. California State Teachers Retirement System now owns 11,384 shares of the company’s stock valued at $875,000 after purchasing an additional 1,335 shares during the last quarter. Polar Asset Management Partners Inc. bought a new position in shares of GeneDx in the fourth quarter valued at approximately $1,007,000. Finally, Palisades Investment Partners LLC acquired a new stake in shares of GeneDx in the fourth quarter worth $6,425,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.